Abstract
The process of developing drugs dates to antiquity. The herbal formulations during the old days were more traditional than with any scientific rationale. As different branches of physics, chemistry and biology started revealing the physiological processes in molecular details and as the sophisticated methods for probing into these phenomena were innovated, the processes of drug development changed significantly. However, the very first step in the process which is defining a drug target remains a major hurdle. The classical methods that predate the functional genomics and proteomics involve a cumbersome, painstaking detailing of a given enzyme or a receptor, followed by its validation as a target. The sophisticated methods in the post-genomic and proteomic era reduced the time taken to define targets, but the speed of drug discovery is not necessarily as quick as it promised. This is primarily due to prolific predictions pressing validation too hard, although both non-robotic and robotic high throughput screenings match with the requirement. Since these drugs target pathogens, a serious disadvantage with these methodologies is the emergence of drug resistance. Therefore, we propose a functional approach whereby the host-pathogen interaction is studied to find out the alterations in immune responses, the profile of host gene expression and activation of cell signaling molecules, the kinases in particular. Such interactions often induce the expression of those genes and activation of those proteins which are required for their survival. We demonstrate that reversal of such profiles of gene expression and protein activation ameliorates the infection. Therefore, those gene products and the kinases with pro-parasitic functions can serve as targets.
Keywords: Drug development strategy, Leishmania infection, host-parasite interaction, Immunomodulation, Immunotherapy, genomics and proteomics, Drug target identification, Drug resistance
Current Medicinal Chemistry
Title: A Novel Functional Approach Toward Identifying Definitive Drug Targets
Volume: 14 Issue: 22
Author(s): Ranadhir Dey, Srijit Khan and Bhaskar Saha
Affiliation:
Keywords: Drug development strategy, Leishmania infection, host-parasite interaction, Immunomodulation, Immunotherapy, genomics and proteomics, Drug target identification, Drug resistance
Abstract: The process of developing drugs dates to antiquity. The herbal formulations during the old days were more traditional than with any scientific rationale. As different branches of physics, chemistry and biology started revealing the physiological processes in molecular details and as the sophisticated methods for probing into these phenomena were innovated, the processes of drug development changed significantly. However, the very first step in the process which is defining a drug target remains a major hurdle. The classical methods that predate the functional genomics and proteomics involve a cumbersome, painstaking detailing of a given enzyme or a receptor, followed by its validation as a target. The sophisticated methods in the post-genomic and proteomic era reduced the time taken to define targets, but the speed of drug discovery is not necessarily as quick as it promised. This is primarily due to prolific predictions pressing validation too hard, although both non-robotic and robotic high throughput screenings match with the requirement. Since these drugs target pathogens, a serious disadvantage with these methodologies is the emergence of drug resistance. Therefore, we propose a functional approach whereby the host-pathogen interaction is studied to find out the alterations in immune responses, the profile of host gene expression and activation of cell signaling molecules, the kinases in particular. Such interactions often induce the expression of those genes and activation of those proteins which are required for their survival. We demonstrate that reversal of such profiles of gene expression and protein activation ameliorates the infection. Therefore, those gene products and the kinases with pro-parasitic functions can serve as targets.
Export Options
About this article
Cite this article as:
Dey Ranadhir, Khan Srijit and Saha Bhaskar, A Novel Functional Approach Toward Identifying Definitive Drug Targets, Current Medicinal Chemistry 2007; 14 (22) . https://dx.doi.org/10.2174/092986707781745523
DOI https://dx.doi.org/10.2174/092986707781745523 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AAV Hybrid Serotypes: Improved Vectors for Gene Delivery
Current Gene Therapy Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Transmission of HIV-1 in the Face of Neutralizing Antibodies
Current HIV Research Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Antiplatelet and Antileukocyte Effects of Cardiovascular,Immunomodulatory and Chemotherapeutic Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA CFTR Inactivation by Lentiviral Vector-mediated RNA Interference and CRISPR-Cas9 Genome Editing in Human Airway Epithelial Cells
Current Gene Therapy Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
Current Cancer Drug Targets